126 related articles for article (PubMed ID: 33372855)
1. Toll-Like Receptor 9 Expression Levels in Breast Carcinoma Correlate with Improved Overall Survival in Patients Treated with Neoadjuvant Chemotherapy and Could Serve as a Prognostic Marker.
Singh A; Bandyopadhyay A; Mukherjee N; Basu A
Genet Test Mol Biomarkers; 2021 Jan; 25(1):12-19. PubMed ID: 33372855
[No Abstract] [Full Text] [Related]
2. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
3. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
5. 15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
Hu M; Li K; Maskey N; Xu Z; Peng C; Tian S; Li Y; Yang G
Int J Clin Exp Pathol; 2015; 8(6):6910-8. PubMed ID: 26261578
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
8. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Chatterjee D; Bal A; Das A; Singh G
Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
[TBL] [Abstract][Full Text] [Related]
9. SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer.
Zhao W; Sun L; Li X; Wang J; Zhu Y; Jia Y; Tong Z
Sci Rep; 2021 Apr; 11(1):8976. PubMed ID: 33903614
[TBL] [Abstract][Full Text] [Related]
10. The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy.
Roininen N; Haapasaari KM; Karihtala P
Oxid Med Cell Longev; 2017; 2017():2908039. PubMed ID: 29348788
[TBL] [Abstract][Full Text] [Related]
11. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
12. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Krug D; Lederer B; Seither F; Nekljudova V; Ataseven B; Blohmer JU; Costa SD; Denkert C; Ditsch N; Gerber B; Hanusch C; Heil J; Hilfrich J; Huober JB; Jackisch C; Kümmel S; Paepke S; Schem C; Schneeweiss A; Untch M; Debus J; von Minckwitz G; Kühn T; Loibl S
Ann Surg Oncol; 2019 Nov; 26(12):3892-3901. PubMed ID: 31350646
[TBL] [Abstract][Full Text] [Related]
13. Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.
Zhao Y; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Jan; 22(1):91-102. PubMed ID: 31006089
[TBL] [Abstract][Full Text] [Related]
14. The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.
Tamirisa N; Williamson HV; Thomas SM; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Hyslop T; Hwang ES; Fayanju OM
J Surg Oncol; 2019 Aug; 120(2):132-141. PubMed ID: 31062375
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
16. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
Tuomela J; Sandholm J; Karihtala P; Ilvesaro J; Vuopala KS; Kauppila JH; Kauppila S; Chen D; Pressey C; Härkönen P; Harris KW; Graves D; Auvinen PK; Soini Y; Jukkola-Vuorinen A; Selander KS
Breast Cancer Res Treat; 2012 Sep; 135(2):481-93. PubMed ID: 22847512
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study.
Ryu JM; Park S; Paik HJ; Nam SJ; Kim SW; Lee SK; Yu J; Bae SY; Kim I; Bang SI; Mun GH; Pyon JK; Jeon BJ; Lee JE
Clin Breast Cancer; 2017 Jun; 17(3):204-210. PubMed ID: 28065399
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.
Berger R; Fiegl H; Goebel G; Obexer P; Ausserlechner M; Doppler W; Hauser-Kronberger C; Reitsamer R; Egle D; Reimer D; Müller-Holzner E; Jones A; Widschwendter M
Cancer Sci; 2010 Apr; 101(4):1059-66. PubMed ID: 20156214
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 9 mediates invasion and predicts prognosis in squamous cell carcinoma of the mobile tongue.
Kauppila JH; Korvala J; Siirilä K; Manni M; Mäkinen LK; Hagström J; Atula T; Haglund C; Selander KS; Saarnio J; Karttunen TJ; Lehenkari PP; Salo T
J Oral Pathol Med; 2015 Sep; 44(8):571-7. PubMed ID: 25338738
[TBL] [Abstract][Full Text] [Related]
20. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
